Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome

Cooperrider, Jennifer H.; Fulton, Noreen; Artz, Andrew S.; Larson, Richard A.; Stock, Wendy; Kosuri, Satyajit; Bishop, Michael; Liu, Hongtao

doi:10.1038/s41409-020-0925-2

Cited by 5 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, selinexor + '3+7' was proven to be a safe regimen, and it produced a median OS of 10.3 months in previously untreated AML patients [65]. Maintenance therapy with selinexor after allogeneic stem cell transplantation in high-risk AML patients was also proven safe and effective [66]. A meta-analysis of the drug's efficacy and safety in AML treatment is in progress [67].…”

Section: Selinexor In Other Hematologic Malignanciesmentioning

confidence: 99%

Selinexor and Other Selective Inhibitors of Nuclear Export (SINEs)—A Novel Approach to Target Hematologic Malignancies and Solid Tumors

Karaszewski,

Jędrzejczak

2023

DDC

View full text Add to dashboard Cite

Exportin 1 (XPO1) is a crucial molecule of nucleocytoplasmic transport. Among others, it exports molecules important for oncogenesis from the nucleus to the cytoplasm. The expression of XPO1 is increased in numerous malignancies, which contributes to the abnormal localization of tumor suppressor proteins in the cytoplasm and subsequent cell cycle dysregulation. Selective inhibitors of nuclear export (SINEs) are novel anticancer agents that target XPO1, arrest tumor suppressor proteins in the nucleus, and induce apoptosis in cancer cells. Selinexor, a first-in-class SINE, has already been approved for the treatment of relapsed/refractory multiple myeloma and relapsed/refractory diffuse large B cell lymphoma not otherwise specified. It has also been proven effective in relapsed/refractory and previously untreated acute myeloid leukemia patients. In addition, numerous studies have yielded promising results in other malignancies of the hematopoietic system and solid tumors. However, future clinical use of selinexor and other SINEs may be hampered by their significant toxicity.

show abstract

Section: Selinexor In Other Hematologic Malignanciesmentioning

confidence: 99%